|
|||||
|
|
Current management of small cell lung cancer |
|
| Authors: | Neal Joel W Gubens Matthew A Wakelee Heather A |
| Affiliation: | a Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA b Thoracic Oncology, University of California, San Francisco, 1600 Divisadero Street, A738, San Francisco, CA 94143-1770, USA |
| Abstract: | Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15%. Extensive stage disease has initial response rates to chemotherapy exceeding 70%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy backbone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development. |
| Keywords: | Small cell lung cancer Limited stage Advanced stage Chemotherapy |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |